Drugs / Lacticaseibacillus paracasei Lpc-37
Lacticaseibacillus paracasei Lpc-37
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04125810 | Sep 2019 → Feb 2020 | — | Danisco | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lacticaseibacillus paracasei Lpc-37 | “Efficacy and safety of Lacticaseibacillus paracasei Lpc-37® in students facing examination stress: A randomized, triple-blind, placebo-controlled clinical trial (the ChillEx study).” PMID 37662485 ↗ Aug 2023 |
| Known as | Lactobacillus Paracasei | “A Randomized, Triple-blind, Placebo-controlled, Parallel-groups Clinical Trial to Assess the Safety and Efficacy of Lactobacillus Paracasei (Lpc-37) to Modulate Psychological Stress” NCT04125810 ↗ |
| Known as | Lpc-37 | “Lacticaseibacillus paracasei Lpc-37 (Lpc-37) has previously shown to reduce perceived stress in healthy adults.” PMID 37662485 ↗ Aug 2023 |
| Modality | Other / unclassified | “In conclusion, probiotic Lpc-37 was safe but had no effect on stress, mood, or anxiety in healthy university students in this model of chronic academic stress.” PMID 37662485 ↗ Aug 2023 |